HR18034

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HemorrhoidInguinal Hernia

72 competitors in Hemorrhoid

#DrugCompanyPhaseTrials

1

Isordil

AstraZeneca

Approved

—2

Marcaine

IInnocoll

Approved

13

Ketalar

AAultman Health Foundation

Approved

14

Cardizem

BBausch Health Americas, Inc.

Approved

15

Nitrostat

VViatris Specialty LLC

Approved

16

Xylocaine

MMEDRx USA, Inc.

Approved

—7

Decadron

AAspen Global Incorporated

Approved

—8

Celestone

SSchering-Plough

Approved

—9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

EXPAREL

Pacira Pharmaceuticals, Inc

Approved

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemorrhoid2 trials

A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.

Completed·Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT05376904·86 enrolled

A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

Completed·Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 3·NCT05769855·294 enrolled

Postsurgical Pain Management2 trials

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

Terminated·Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT06509958·15 enrolled

Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management

Unknown status·Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT05744674·96 enrolled

Inguinal hernia1 trial

A Trial of HR18034 in Inguinal Hernia Repair

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04551924·64 enrolled

Details

Drug Info

Related News